Orion Oyj Class A · OMXHEX:ORNAV
Orion Oyj Class A — Q1 2024 Earnings Presentation
18 slides from Orion Oyj Class A's earnings presentation, Apr 25, 2024
Slide 1: Orion Interim Report January–March 2024 Result Presentation
Orion Interim Report January–March 2024 Result Presentation 25 April 2024
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Q1 2024 – Year started well with strong topline growth
Q1 2024 – Year started well with strong topline growth • Growth came from various sources 1–3/ 1–3/ • Nubeqa® and Easyhaler® product portfolio continued Change 2024 2023 to be the largest drivers of growth Net sales, EUR million 308.5 277.9 +11.0% • Operating profit flat due to a planned increase in
Slide 4: Net sales bridge from Q1'2023 to Q1'2024
Net sales bridge from Q1’2023 to Q1’2024 1 Simdax® and dexmedetomidine for human use 5 Other products and services (excl. Animal Health and Fermion) 2 Nubeqa® (product sales and royalty) 6 Animal Health and Fermion 3 Entacapone products 7 Milestones 4 Easyhaler® product portfolio 8 Exchange rates 5
Slide 5: Operating profit bridge from Q1'2023 to Q1'2024
Operating profit bridge from Q1’2023 to Q1’2024 1 Product & service sales without sales margin and product mix change and exchange rate effect 5 Milestones 2 Product sales margin and product mix change but without exchange rate effect 6 Other operating income and expenses 3 Exchange rate effect on g
Slide 6: Innovative Medicines EUR 57.4 million (+37.4%)
Innovative Medicines EUR 57.4 million (+37.4%) • Nubeqa® sales booked by Orion were EUR 49.5 Nubeqa® sales booked by Orion1 million (+31.3%) 70 • Royalty rate starts from the lowest tier every calendar 60 year • All-time high product deliveries to Bayer in Q4’2023 50 and second highest ever in Q1’20
Slide 7: Branded Products EUR 70.2 million (+17.9%)
Branded Products EUR 70.2 million (+17.9%) 45 • Easyhaler® product portfolio 41.9 Sales split 40 showed again very strong 4% growth 35 32.2 • Other products performed as 30 8% expected 25 MEUR 21.5 20.0 20 15 29% 10 60% 4.9 5.5 5 2.7 1.0 0 Easyhaler® Entacapone 1–3/2023 1–3/2024 Divina® series Other
Slide 8: Generics and Consumer Health EUR 130.7 million (-2.2%)
Generics and Consumer Health EUR 130.7 million (-2.2%) 120 • Generic competition pressing Sales split by geographic the prices and sales of Simdax® 101.1 96.8 areas and dexmedetomidine products 100 for human use 80 • Excluding Simdax®, 14% dexmedetomidine products for MEUR 60 human use and Russia1,
Slide 9: Animal Health and Fermion
Animal Health and Fermion • Animal Health growth (+18.2%) Animal Health Fermion came from various sources with 35 35 31.9 animal sedatives being the single 30 30 largest contributor 26.9 10.3 25 25 8.0 20 20 18.1 18.5 MEUR 15 15 10 21.6 10 18.9 5 5 0 0 1–3/2023 1–3/2024 1–3/2023 1–3/2024 Sedatives p
Slide 10: TOP products and total sales split by division
TOP 10 products and total sales split by division EUR vs. Product or product portfolio million 1–3/2023 Sales split in 1–3/2024 1. Nubeqa® 49.5 +31.3% 2. Easyhaler® product portfolio 41.9 +30.2% 3. Entacapone products1 20.0 -6.7% 6% 10% 19% 4. Dexdomitor®, Domitor®, Domosedan®, Antisedan® 10.3 +27.5
Slide 11: Key clinical development pipeline
Key clinical development pipeline Project/compound Indication PHASE I PHASE II PHASE III REGISTRATION ARANOTE / darolutamide 1 Prostate cancer (mHSPC) Ongoing ARASTEP / darolutamide 1 Prostate cancer (BCR) Ongoing OMAHA1 / ODM-208 (MK-5684-003) 2 Prostate cancer (mCRPC) Ongoing OMAHA2a / ODM-208 (MK
Slide 12: Sustainability Report 2023 is now available on our website
Sustainability Report 2023 is now available on our website – these are Orion’s sustainability highlights from 2023 Patient safety Active work for a Care for well-being Ethics at the core as a top priority better environment professionals of our business Despite a challenging global We successfully i
Slide 13: Outlook for 2024 (specified)
Outlook for 2024 (specified) Net sales EUR 1,340–1,410 million Operating EUR 280–310 million profit 14 25 April 2024 © Orion Corporation
Slide 14: Basis for the outlook – key contributors
Basis for the outlook – key contributors Net sales EUR 1,340–1,410 million Operating profit EUR 280–310 million Innovative Medicines • Expected growth driven by Nubeqa® royalties and assumed EUR 70 million Nubeqa® milestone Nubeqa® sales booked by Orion • Difficult to predict the exact level of
Slide 15: Orion's strategy period 2024–2028 – key takeaways
Orion’s strategy period 2024–2028 – key takeaways Financial objectives provide us a framework to operate and maintain the right balance between expenditure and profitability Increasing Growing EBIT Growing investments to and annually Enable AND revenues build the future increasing of Orion dividend
Slide 16: Capital allocation focus
Capital allocation focus In-licensing / Focused Maintaining In-licensing / Internal R&D acquiring M&As to gain Dividends & increasing acquiring pipeline commercial strategic capacity R&D assets assets competences Higher Lower 17
Slide 17: Financial objectives
Financial objectives Strategy period 2024–2028 Net sales Operating profit CAGR ≥8% To grow faster than net sales Equity ratio ROE ≥50% ≥25% Dividend Annually increasing dividend – payout ratio 50%–100% 18 25 April 2024 © Orion Corporation
Slide 18: Upcoming events
Upcoming events Half-Year Financial Report 1–6/2024 8/8/2024 Interim Report 1–9/2024 29/10/2024